Brivaracetam in the treatment of patients with epilepsy

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Search result: 0

Karlov V.A.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

Vlasov P.N.

GBUZ MO "Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii", Moskva

Zhidkova I.A.

Kafedra nervnykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Kissin M.Ia.

Lebedeva A.V.

FGBU "Federal'nyĭ nauchnyĭ tsentr transplantologii i iskusstvennykh organov im. akad. V.I. Shumakova" Minzdrava Rossii, Moskva

SPIN RSCI: 3515-2408
Scopus AuthorID: 57193881028
ORCID: 0000-0001-8712-4775

Lipatova L.V.

Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva, Sankt-Peterburg

Mkrtchyan V.R.

Z.P. Solovyov Research and Practical Psychoneurology Center, Moscow Healthcare Department, Moscow, Russia

Mukhin K.Iu.

Kafedra nervnykh bolezneĭ pediatricheskogo fakul'teta s kursom fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Rudakova I.G.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo, Moskva

Brivaracetam in the treatment of patients with epilepsy

Authors:

Karlov V.A., Vlasov P.N., Zhidkova I.A., Kissin M.Ia., Lebedeva A.V., Lipatova L.V., Mkrtchyan V.R., Mukhin K.Iu., Rudakova I.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9‑2): 55‑62

DOI: 10.17116/jnevro20171179255-62

Read: 4727 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Karlov VA, Vlasov PN, Zhidkova IA, et al. Brivaracetam in the treatment of patients with epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9‑2):55‑62. (In Russ.)
https://doi.org/10.17116/jnevro20171179255-62

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Abstract:

The newest antiepileptic drug (AED) brivaracetam (Briviac, UCB Pharma) (BRV) was approved in the Russian Federation in 2017 as an adjuvant therapy for the treatment of partial seizures with/without secondary generalization in adults and adolescents over 16 years old with epilepsy. This review contains the data of BRV preclinical studies, pharmacokinetic profile and the results of comparative study of BRV and LEV. The results of main studies of efficacy and tolerability with pooled analysis as well as data from meta-analysis are presented. The authors present conclusions of the Russian leading epileptologists on perspectives of using BRV in different populations of epileptic patients. The use of BRV is able to provide long-term efficacy in terms of seizure control, is well tolerated, keeps quality of life and social activity of people with epilepsy

Keywords:

epilepsy

partial seizures

adjunctive therapy

antiepileptic drugs

brivaracetam

mechanism of action

efficacy

tolerability

SV2A

Authors:

Karlov V.A.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

Vlasov P.N.

GBUZ MO "Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii", Moskva

Zhidkova I.A.

Kafedra nervnykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Kissin M.Ia.

Lebedeva A.V.

FGBU "Federal'nyĭ nauchnyĭ tsentr transplantologii i iskusstvennykh organov im. akad. V.I. Shumakova" Minzdrava Rossii, Moskva

SPIN RSCI: 3515-2408
Scopus AuthorID: 57193881028
ORCID: 0000-0001-8712-4775

Lipatova L.V.

Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva, Sankt-Peterburg

Mkrtchyan V.R.

Z.P. Solovyov Research and Practical Psychoneurology Center, Moscow Healthcare Department, Moscow, Russia

Mukhin K.Iu.

Kafedra nervnykh bolezneĭ pediatricheskogo fakul'teta s kursom fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Rudakova I.G.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo, Moskva

Close metadata

References:

Karlov VA, Gekht AB, Guzeva VI, Lipatova LV, Bazilevich SN, Mkrtchan VR, Vlasov PN, Zhidkova IA, Mukhin KYu, Petrukhin AS, Lebedeva AV. Algorithms of mono- and polytherapy in clinical epileptology. Part 1. General principles of the choice of pharmacotherapy. Zh Nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116:6:109-114. (In Russ.)
Karlov VA, Gekht AB, Guzeva VI, Lipatova LV, Bazilevich SN, Mkrtchan VR, Vlasov PN, Zhidkova IA, Mukhin KYu, Petrukhin AS, Lebedeva AV. Algorithms of mono- and polytherapy in clinical epileptology. Part 2. Features of treatment of individual patient groups. Zh Nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116:7:120-129. (In Russ.)
Loscher Wolfgang, Michel Gillard, Zara A. Sands, Rafal M. Kaminski, Henrik Klitgaard3 Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond CNS Drugs. 2016;116:30:1055-1077. https://doi.org/10.1007/s40263-016-0384-x
Instruktsiya po primeneniyu Briviak. Registratsionnoe udostoverenie lekarstvennogo preparata dlya meditsinskogo primeneniya. LP-004084-180117. http://grls.rosminzdrav.ru/
Gillard M, Fuks B, Leclercq K, et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664:36-44. https://doi.org/10.1016/j.ejphar.2011.04.064
Wasterlain CG, Suchomelova L, Matagne A, et al. Shortterm and long-term effects of brivaracetam in an animal model of status epilepticus. Epilepsia. 2009;50(10):13.
NCT02602860 Clinical Trial Study Record: Available online at https://clinicaltrials.gov/ct2/show/NCT02602860?term=NCT02602860&rank=1. (Last accessed: 16/06/2016).
Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008;154(8):1662-1671. https://doi.org/10.1038/bjp.2008.198
Detrait ER, Leclercq K, Loscher W, et al. Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats. Epilepsy Res. 2010;91(1):74-83. https://doi.org/10.1016/j.eplepsyres.2010.06.014
Sargentini-Maier ML, Esple P, Coquette A, et al. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008;36:36-45. [E Pub 2007 Oct 1]. https://doi.org/10.1124/dmd.107.017129
Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015;111:85-141. [Epub 2015 Jan 19] https://doi.org/10.1016/j.eplepsyres.2015.01.001
Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia. 2014;55(3):27-31. [Epub 2014 Feb 11]. https://doi.org/10.1111/epi.12535.
Stockis A, Sargentini-Maiera ML, Brodie MJ. Pharmacokinetic interaction of brivaracetam on carbamazepine inadult patients with epilepsy, with and without valproateco-administration. Epilepsy Research. 2006;128:163-168. https://doi.org/10.1016/j.eplepsyres.2016.11.001
Kruithof AC, Watanabe S, Peeters PAM, de Kam ML, Zuiker RGJA, Stevens J, MA van Gerven J, Stockis A. Pharmacological interactions between brivaracetam and ethanol in healthy males. Journal of Psychopharmacology. 2016:0269881116665326. https://doi.org/10.1177/0269881116665326
Niespodziany I, André VM, Leclère N, Hanon E, Ghisdal P, Wolff C. Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neurons. CNS Neurosci Ther. 2015;21:241-251. https://doi.org/0.1111/cns.12347
Klein P, Schiemann J, Sperling MR, et al. A randomized, double- blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890-1898. https://doi.org/10.1111/epi.13212
Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology. 2016;86:1344-1352. https://doi.org/10.1212/wnl.0000000000002545.
French JA, Costantini C, Brodsky A, von Rosenstiel P, Group NS. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010;75(6):519-525. https://doi.org/10.1212/wnl.0b013e3181ec7f7f
Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013;54(1):89-97. https://doi.org/10.1111/j.1528-1167.2012.03598.x
Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57-66. https://doi.org/10.1111/epi.12433
Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive bri- varacetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47-56. https://doi.org/10.1111/epi.12432
Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55(1):38-46. https://doi.org/10.1111/epi.12391
Ma J, Siqing Huang, Chao You Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials Epilepsy Research. 2015;114:59-65. https://doi.org/10.1016/j.eplepsyres.2015.04.017
Tian X, Meizhen Yuan, Qingju Zhou & Xuefeng Wang†The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies Expert Opin. Pharmacother. 2015;16(12):1755-1767.
Ben-Menachem E, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016;87(3):314-323. https://doi.org/10.1212/WNL.0000000000002864
Klein P, Johnson ME, Schiemann J, Whitesides J. Time to onset of sustained≥ 50% responder status in patients with focal (partial‐onset) seizures in three phase III studies of adjunctive brivaracetam treatment. Epilepsia. 2017;58(2):21-25. https://doi.org/10.1111/epi.13631
Zhu Li-na, Chen Deng, Chen Tao, Xu Da, Chen Si-han, Liu Ling. The adverse event profile of brivaracetam: A meta-analysis of randomized controlled trials. Seizure. 2017;45:7-16. https://doi.org/10.1016/j.seizure.2016.11.008
Yates S, Fakhoury T, Liang W, Eckhardt K, Borghs S, d’Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52:165-168. https://doi.org/10.1016/j.yebeh.2015.09.005
Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B, Borghs S, Kwan P. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016;57(7):1139-1151. https://doi.org/10.1111/epi.13416
Brandt Ch, Borghs S, Elmoufti S, Mueller K, Townsend R, de la Loge Ch. Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis. Epilepsy & Behavior. 2017;69:80-85. https://doi.org/10.1016/j.yebeh.2016.11.031
Wasterlain CG, Suchomelova L, Matagne A, et al. Shortterm and long-term effects of brivaracetam in an animal model of status epilepticus. Epilepsia. 2009;50(Suppl. 10):13.
Tai KK, Truong DD. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. J Neural Transm. 2007;114(12):1547-1551. https://doi.org/10.1007/s00702-007-0788-3
Kasteleijn-Nolst Trenité DGA, Genton P, Parain D, Masnou P, Steinhoff BJ, Jacobs T, Pigeolet E, Stockis A, Hirsch E. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology. 2007;69:1027-1034. https://doi.org/10.1212/01.wnl.0000271385.85302.55
Cross JH, Kluger G, Lagae L. Advancing the management of childhood epilepsies. Eur J Paediatr Neurol. 2013;17(4):334-347. https://doi.org/10.1016/j.ejpn.2013.02.003

Log in to the site using your account in one of the services

Registration

Last Name

Name

Middle Name

E-mail

Phone

Address

Country

Zip

City

Region

Street

Home

Apartmen

Legal entity name

ИНН

КПП

Password

Password

Repeat password

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.